Last week, the Department of Clinical Research organized a Clinical Research Day to showcase the latest achievements in clinical research. The event aimed to highlight the work of the department's talented researchers, including some of our very own RC2NB team comprising Perrine Janiaud, Jens Kuhle, Lars Hemkens and Özgür Yaldizli. One of the standout talks during the event was presented by Perrine Janiaud, shedding light on significant progress in Multiple Sclerosis (MS) research.
Talk Summary: Leveraging sNfL for Personalized MS Care
Perrine discussed using serum neurofilament light chain (sNfL) as a sensitive marker for neuronal damage in MS. This marker provides valuable insights into disease activity and treatment response, offering a promising avenue for tailoring treatment decisions to individual patients with MS.
Through a Delphi study involving international MS experts and patient consultants, a consensus was achieved on treatment escalation, switching, and de-escalation algorithms based on sNfL levels. This consensus marks a significant step towards more personalized care for individuals with MS.
The next phase involves implementing these algorithms in a randomized pragmatic clinical trial known as the MultiSCRIPT trial. This trial is embedded within the Swiss MS cohort and assesses the benefits of 6-monthly sNfL monitoring compared to usual care. The trial aims to provide further evidence and insights into the potential advantages of incorporating sNfL monitoring into routine clinical practices.
Stay tuned for more updates on the MultiSCRIPT trial as the RC2NB team continues its efforts to advance personalized care for individuals with MS. The strides made in this research not only contribute to the scientific understanding of MS but also hold the promise of improving the lives of those affected by this complex neurological condition.
